In HER2-expressing breast tumor treated with ADCs, pre-clinical mouse model studies revealed that the expression of PD-1 in CD8+ T cells and of PD-L1 on tumor cells/tumor-associated macrophages is upregulated and tumor-infiltrating lymphocytes were also revealed to be increased compared with in the vehicle control. This evidence concerns the gene ERBB2 and neoplasm.